Trending Now
Amicus Therapeutics Inc. (NASDAQ:FOLD) Reports Q3 2020 Financial Results With Galafold...
Amicus Therapeutics Inc. (NASDAQ:FOLD) has announced its Q3 2020 financial results for the quarter ended September 30, 2020, in which Galafold revenue was $67.4...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) Report Positive GENEr8-1 Study Of...
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) has announced positive findings from ongoing worldwide third phase GENEr8-1 trial of valoctocogene roxaparvovec, experimental gene therapy for severe...
MAKE IT MODERN
LATEST REVIEWS
Sangamo Therapeutics Inc (NASDAQ:SGMO) Inks A Collaboration Agreement With Novartis AG...
Sangamo Therapeutics Inc (NASDAQ:SGMO) entered an international licensing collaboration accord with Novartis AG (NYSE:NVS) to commercialize/ develop gene regulation therapies (GRT).
GRT targets ASD
Sangamo will...
MAKE IT MODERN
PERFORMANCE TRAINING
Evofem Biosciences Inc (NASDAQ: EVFM) Reports Q2 2022 Financial Results With Phexxi Sales of...
Evofem Biosciences Inc (NASDAQ: EVFM) has announced its financial results for the quarter and six months that ended June 30, 2022, and affirmed its...
Vericel Corporation Inc. (NASDAQ:VCEL) Posts Net Revenue Of $32.3 Million In Q3 2020
Vericel Corporation Inc. (NASDAQ:VCEL) has announced its Q3 2020 financial results posting net revenue of $32.3 million and also provided business updates.
Vericel reports total...
Catalyst Pharmaceutical Inc.’s (NASDAQ: CPRX) Japanese Partner DyDo Pharma Commences Registrational Study of FIRDAPSE
Catalyst Pharmaceutical Inc. (NASDAQ: CPRX) has announced that its partner DyDo Pharma has commenced third phase registrational stud in Japan evaluating the safety and...
Would Summit Therapeutics Inc (NASDQ:SMMT) resort to dilution to raise cash
Summit Therapeutics Inc (NASDQ:SMMT) last traded on Friday at $3.61. The recent surge is attributed to news that it's licensing bispecific antibody...
XORTX Therapeutics Inc ($XRTX): Pioneering New Treatments for Kidney Disease with a Precision-Medicine Approach
Today, XORTX Therapeutics Inc. (NASDAQ: XRTX) experienced a remarkable surge in its stock price, closing at $2.18 USD—a stunning 86.44% increase. The...
MAKE IT MODERN
